• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.玻璃体内注射后经培养证实的眼内炎:一项10年分析
Ophthalmic Surg Lasers Imaging Retina. 2019 Jan 1;50(1):33-38. doi: 10.3928/23258160-20181212-05.
2
MICROBIAL SPECTRUM AND OUTCOMES OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION VERSUS PARS PLANA VITRECTOMY.玻璃体腔内注射与玻璃体切割术后眼内炎的微生物谱及预后
Retina. 2016 Feb;36(2):351-9. doi: 10.1097/IAE.0000000000000694.
3
Characteristics and Outcomes of Endogenous Endophthalmitis: Eight-Year Experience at a Tertiary Care Center.内源性眼内炎的特征与转归:三级医疗中心的八年经验
Ophthalmol Retina. 2019 Jan;3(1):61-72. doi: 10.1016/j.oret.2018.08.009. Epub 2018 Sep 6.
4
Comparative Study of Microbiological Profile and Management Outcomes of Acute Endophthalmitis after Microincision Vitrectomy Surgery versus Intravitreal Injections.微创玻璃体切割术后与玻璃体内注射后急性眼内炎的微生物谱和治疗结局的对比研究。
Ocul Immunol Inflamm. 2021 Jul 4;29(5):838-844. doi: 10.1080/09273948.2019.1695858. Epub 2020 Jan 3.
5
MICROBIOLOGIC SPECTRUM AND VISUAL OUTCOMES OF ACUTE-ONSET ENDOPHTHALMITIS UNDERGOING THERAPEUTIC PARS PLANA VITRECTOMY.接受治疗性玻璃体切割术的急性发作性眼内炎的微生物谱及视力预后
Retina. 2017 Jul;37(7):1246-1251. doi: 10.1097/IAE.0000000000001358.
6
Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.玻璃体培养指导下内眼注药后眼内炎治疗策略的改变
Am J Ophthalmol. 2019 Nov;207:224-231. doi: 10.1016/j.ajo.2019.06.008. Epub 2019 Jun 13.
7
Endogenous endophthalmitis: a 10-year review of culture-positive cases in northern China.内源性眼内炎:中国北方 10 年阳性培养病例回顾。
Ocul Immunol Inflamm. 2010 Apr;18(2):133-8. doi: 10.3109/09273940903494717.
8
Clinical presentations, risk factors and outcomes of ceftazidime-resistant Gram-negative endophthalmitis.耐头孢他啶革兰阴性菌性眼内炎的临床表现、危险因素及预后
Clin Exp Ophthalmol. 2017 Apr;45(3):254-260. doi: 10.1111/ceo.12833. Epub 2016 Oct 11.
9
Clinical and microbiologic review of culture-proven endophthalmitis caused by multidrug-resistant bacteria in patients seen at a tertiary eye care center in southern India.印度南部一家三级眼科中心所见耐多药细菌引起的内眼感染的临床和微生物学回顾。
Retina. 2011 Oct;31(9):1806-11. doi: 10.1097/IAE.0b013e31820f4b9d.
10
Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes.经培养证实的内源性眼内炎:临床特征及视力预后
Am J Ophthalmol. 2004 Apr;137(4):725-31. doi: 10.1016/j.ajo.2003.11.013.

引用本文的文献

1
Delayed-onset endophthalmitis following intravitreal injection.玻璃体内注射后迟发性眼内炎。
Am J Ophthalmol Case Rep. 2025 Jun 28;39:102370. doi: 10.1016/j.ajoc.2025.102370. eCollection 2025 Sep.
2
Timing of vitrectomy for treatment of endophthalmitis after intravitreal anti-VEGF injection: a systematic literature review of case reports and series.玻璃体内注射抗VEGF药物后发生眼内炎行玻璃体切割术的时机:病例报告及系列病例的系统文献综述
Ther Adv Ophthalmol. 2025 Jan 16;17:25158414241311064. doi: 10.1177/25158414241311064. eCollection 2025 Jan-Dec.
3
Outcomes of a Multicenter 10-Year Review of Postinjection Endophthalmitis and Associated Systemic Medical Comorbidities.注射后眼内炎及相关全身性内科合并症的多中心10年回顾结果
J Vitreoretin Dis. 2023 Sep 29;7(6):504-509. doi: 10.1177/24741264231200738. eCollection 2023 Nov-Dec.
4
Morganella morganii and Enterococcus faecalis endophthalmitis following intravitreal injection.眼内注射后摩根摩根菌和粪肠球菌性眼内炎。
BMC Ophthalmol. 2023 Nov 10;23(1):450. doi: 10.1186/s12886-023-03198-4.
5
Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection.临床实践更新:玻璃体内抗血管内皮生长因子注射后感染性眼内炎的管理
J Vitreoretin Dis. 2022 Sep 8;6(6):443-451. doi: 10.1177/24741264221116487. eCollection 2022 Nov-Dec.
6
Treatment Patterns and Outcomes in Bleb-Related Endophthalmitis: A 9-Year Analysis at a Tertiary Eye Center.与滤过泡相关的眼内炎的治疗模式及预后:一家三级眼科中心的9年分析
J Vitreoretin Dis. 2020 Sep 17;5(2):130-134. doi: 10.1177/2474126420953963. eCollection 2021 Mar-Apr.
7
Management Patterns and Outcomes for Intravitreal Injection-Related Endophthalmitis.玻璃体内注射相关性眼内炎的管理模式与结局
J Vitreoretin Dis. 2021 Jul 28;6(3):188-193. doi: 10.1177/24741264211028435. eCollection 2022 May-Jun.
8
Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.注射相关性眼内炎的预防因素、诊断和处理:文献综述。
Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2399-2416. doi: 10.1007/s00417-022-05607-8. Epub 2022 Mar 12.

本文引用的文献

1
Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.眼内注射血管内皮生长因子抑制剂后的眼内炎:处理和视力结果。
Ophthalmology. 2018 Aug;125(8):1279-1286. doi: 10.1016/j.ophtha.2018.01.022. Epub 2018 Feb 21.
2
The 2016 American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Database: Characteristics and Methods.2016 年美国眼科学会虹膜注册研究(智能视野研究)数据库:特征和方法。
Ophthalmology. 2018 Aug;125(8):1143-1148. doi: 10.1016/j.ophtha.2017.12.001. Epub 2018 Jan 17.
3
Predictors of visual outcome and the role of early vitrectomy in streptococcal endophthalmitis: response.链球菌性眼内炎视觉预后的预测因素及早期玻璃体切除术的作用:回应
Clin Exp Ophthalmol. 2018 Jul;46(5):578. doi: 10.1111/ceo.13130. Epub 2018 Jan 10.
4
Trends in Vitreoretinal Procedures for Medicare Beneficiaries, 2000 to 2014.2000 年至 2014 年 Medicare 受益人群的玻璃体视网膜手术趋势。
Ophthalmology. 2017 May;124(5):667-673. doi: 10.1016/j.ophtha.2017.01.001. Epub 2017 Mar 7.
5
POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS.玻璃体内注射抗血管内皮生长因子药物时使用和不使用局部抗生素预防措施的眼内炎发生率的合并估计值。
Retina. 2018 Jan;38(1):1-11. doi: 10.1097/IAE.0000000000001583.
6
Enterococcus Species in the Oral Cavity: Prevalence, Virulence Factors and Antimicrobial Susceptibility.口腔中的肠球菌属:患病率、毒力因子及药敏性
PLoS One. 2016 Sep 15;11(9):e0163001. doi: 10.1371/journal.pone.0163001. eCollection 2016.
7
Antibioprophylaxis in Prevention of Endophthalmitis in Intravitreal Injection: A Systematic Review and Meta-Analysis.玻璃体内注射时抗生素预防眼内炎的系统评价和Meta分析
PLoS One. 2016 Jun 3;11(6):e0156431. doi: 10.1371/journal.pone.0156431. eCollection 2016.
8
Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.玻璃体内注射贝伐单抗、雷珠单抗和阿柏西普后的注射后眼内炎发生率及特征
Am J Ophthalmol. 2016 May;165:88-93. doi: 10.1016/j.ajo.2016.02.028. Epub 2016 Mar 2.
9
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms.玻璃体内注射抗VEGF药物后发生的眼内炎:长期预后及罕见微生物的鉴定
J Ophthalmic Inflamm Infect. 2016 Dec;6(1):2. doi: 10.1186/s12348-015-0069-5. Epub 2016 Jan 12.
10
MICROBIAL SPECTRUM AND OUTCOMES OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION VERSUS PARS PLANA VITRECTOMY.玻璃体腔内注射与玻璃体切割术后眼内炎的微生物谱及预后
Retina. 2016 Feb;36(2):351-9. doi: 10.1097/IAE.0000000000000694.

玻璃体内注射后经培养证实的眼内炎:一项10年分析

Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

作者信息

Simonett Joseph M, Igelman Austin, Taylor Stanford C, Campbell J Peter, Hwang Thomas S, Lin Phoebe, Lauer Andreas K, Flaxel Christina J

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2019 Jan 1;50(1):33-38. doi: 10.3928/23258160-20181212-05.

DOI:10.3928/23258160-20181212-05
PMID:30640393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7875494/
Abstract

BACKGROUND AND OBJECTIVE

To report on the microbiology, management, and visual outcomes of intravitreal injection (IVI)-associated, culture-proven endophthalmitis.

PATIENTS AND METHODS

All patients seen at a tertiary referral center with culture-proven endophthalmitis associated with an IVI between June 2007 and July 2017 were included in this retrospective analysis.

RESULTS

Thirty-five patients with culture-positive endophthalmitis following IVI were identified. All gram-positive organisms (34 of 35) were susceptible to vancomycin. Cases due to pathogens associated with oral or respiratory flora were common (31.4%, n = 11), presented earlier (2.0 days vs. 4.6 days, P < .001), were more likely to undergo pars plana vitrectomy (81.8% vs. 25.0%, P = .002) and had worse visual acuity outcomes.

CONCLUSION

IVI-associated endophthalmitis pathogens and anti-microbial susceptibilities in the Pacific Northwest are similar to those reported from other geographic locations. Bacteria associated with the oral and respiratory flora are common isolates that result in a more aggressive course and worse visual outcomes. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:33-38.].

摘要

背景与目的

报告玻璃体内注射(IVI)相关的、经培养证实的眼内炎的微生物学、治疗及视力预后情况。

患者与方法

本回顾性分析纳入了2007年6月至2017年7月间在一家三级转诊中心就诊的、经培养证实与玻璃体内注射相关的眼内炎患者。

结果

共确定了35例玻璃体内注射后培养阳性的眼内炎患者。所有革兰氏阳性菌(35例中的34例)对万古霉素敏感。由与口腔或呼吸道菌群相关的病原体引起的病例很常见(31.4%,n = 11),发病更早(2.0天对4.6天,P < .001),更有可能接受玻璃体切割术(81.8%对25.0%,P = .002),且视力预后更差。

结论

太平洋西北地区玻璃体内注射相关眼内炎的病原体及抗菌药敏情况与其他地理位置报告的情况相似。与口腔和呼吸道菌群相关的细菌是常见的分离菌,会导致更具侵袭性的病程和更差的视力预后。[《眼科手术、激光与视网膜成像》。2019;50:33 - 38。]